NMNwando Mba

Nwando Mba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nwando Mba has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lessons learnt from laboratory capacity building in supporting integrated disease serosurveillance using a multiplex bead assay in Nigeria

    by Ado G. Abubakar, Mary Okoli, Oluwaseun O. Akinmulero, Andrew Thomas, Temitope A. Olaleye, Simon Gabo, Samuel S. Awala, Felicia Nwatu, Blessing Ugboaja, Ifeanyi Odoh, et al.

    Background: Serologic assays can monitor population exposure to pathogens and immunity to vaccine-preventable diseases; the multiplex bead assay (MBA) can test for multiple analytes simultaneously. Intervention: Specimens collected during the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) were used to estimate the seroprevalence of diseases of public health importance, and specimens collected from special studies were used to estimate the seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to improve the surveillance programmes. In 2019, Luminex MAGPIX® instruments were installed at the MBA laboratory in the National Reference Laboratory, Nigeria Centre for Disease Control and Prevention, in Abuja, Nigeria. Dried blood spot specimens from the NAIIS, stored with consent for future testing, were prioritised for testing. Between 2019 and 2022, the National Reference Laboratory MBA laboratory conducted antibody and antigen assays for an estimated 130 000 NAIIS participants, completed two rounds of coronavirus disease 2019 (COVID-19) serosurveys, and validated SARS-CoV-2 serological assays for use in Nigeria. Lessons learnt: The data generated by the MBA laboratory supported funding requests for childhood immunisation and the application of the National Malaria Elimination Programme Global Fund. The MBA results strengthened the National HIV Serial Rapid Testing Algorithm. During the COVID-19 pandemic, the laboratory validated a SARS-CoV-2 MBA, which measured antibodies against three antigens. This multi-target assay was used to complete two additional rounds of the COVID-19 household serosurvey in Nigeria. Recommendations: This strategy of investing in MBA laboratory capacity building could serve as a model for other nations seeking to fortify their public health infrastructure. What this study adds: Nigeria’s integrated disease surveillance capability was boosted through MBA technology.


  • Open Access

    Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria

    by Nnaemeka C. Iriemenam, Fehintola A. Ige, Stacie M. Greby, Olumide O. Okunoye, Mabel Uwandu, Maureen Aniedobe, Stephnie O. Nwaiwu, Nwando Mba, Mary Okoli, Nwachukwu E. William, et al.


  • Open Access

    Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort

    by Omotayo Bolu, Usman Adamu, Richard Franka, Chukwuma David Umeokonkwo, Qian An, Stacie Greby, Sharla McDonald, Bernardo Mainou, Nwando Mba, Ndidi Agala, et al.

    INTRODUCTION: In 2016, a switch from trivalent oral poliovirus vaccine (OPV) (containing serotypes 1,2,3) to bivalent OPV (types 1,3) was implemented globally. We assessed the seroprevalence of poliovirus antibody levels in selected Nigerian states, before and after the switch, documented poliovirus type2 outbreak responses conducted and ascertained factors associated with immunity gaps based on seroprevalence rates. METHODS: we conducted a secondary analysis of stored serum samples from the 2018 Nigeria National HIV/AIDS Indicator and Impact Survey. Serum from 1,185 children aged 0-119 months residing in one southern and four northern states were tested for serotype-specific PV neutralizing antibodies; seropositivity was a reciprocal titer ?8. We conducted regression analysis to determine sociodemographic risk factors associated with low seroprevalence using SAS 9.4. RESULTS: children aged 24-119 months (pre-switch cohort) had seroprevalence against PV1, PV2, and PV3, of 97.3% (95% CI:96.4-98.2), 93.8% (95% CI:92.2-95.5), and 91.3% (95% CI:89.2-93.4), while children aged


  • Open Access

    Evaluation of the Nigeria national HIV rapid testing algorithm

    by Nnaemeka C. Iriemenam, Augustine Mpamugo, Akudo Ikpeazu, Olumide O. Okunoye, Edewede Onokevbagbe, Orji O. Bassey, Jelpe Tapdiyel, Matthias A. Alagi, Chidozie Meribe, Mukhtar L. Ahmed, et al.

    Human Immunodeficiency Virus (HIV) diagnosis remains the gateway to HIV care and treatment. However, due to changes in HIV prevalence and testing coverage across different geopolitical zones, it is crucial to evaluate the national HIV testing algorithm as false positivity due to low prevalence could be detrimental to both the client and the service delivery. Therefore, we evaluated the performance of the national HIV rapid testing algorithm using specimens collected from multiple HIV testing services (HTS) sites and compared the results from different HIV prevalence levels across the six geopolitical zones of Nigeria. The evaluation employed a dual approach, retrospective, and prospective. The retrospective evaluation focused on a desktop review of program data (n = 492,880) collated from patients attending routine HTS from six geopolitical zones of Nigeria between January 2017 and December 2019. The prospective component utilized samples (n = 2,895) collected from the field at the HTS and tested using the current national serial HIV rapid testing algorithm. These samples were transported to the National Reference Laboratory (NRL), Abuja, and were re-tested using the national HIV rapid testing algorithm and HIV-1/2 supplementary assays (Geenius to confirm positives and resolve discordance and multiplex assay). The retrospective component of the study revealed that the overall proportion of HIV positives, based on the selected areas, was 5.7% (28,319/492,880) within the study period, and the discordant rate between tests 1 and 2 was 1.1%. The prospective component of the study indicated no significant differences between the test performed at the field using the national HIV rapid testing algorithm and the re-testing performed at the NRL. The comparison between the test performed at the field using the national HIV rapid testing algorithm and Geenius HIV-1/2 supplementary assay showed an agreement rate of 95.2%, while that of the NRL was 99.3%. In addition, the comparison of the field results with HIV multiplex assay indicated a sensitivity of 96.6%, the specificity of 98.2%, PPV of 97.0%, and Kappa Statistic of 0.95, and that of the NRL with HIV multiplex assay was 99.2%, 99.4%, 99.0%, and 0.99, respectively. Results show that the Nigeria national serial HIV rapid testing algorithm performed very well across the target settings. However, the algorithm’s performance in the field was lower than the performance outcomes under a controlled environment in the NRL. There is a need to target testers in the field for routine continuous quality improvement implementation, including refresher trainings as necessary.


  • Open Access

    Epidemiology, diagnostics and factors associated with mortality during a cholera epidemic in Nigeria, October 2020–October 2021: a retrospective analysis of national surveillance data

    by Kelly Elimian, Sebastian Yennan, Anwar Musah, Iliya Danladi Cheshi, Carina King, Lauryn Dunkwu, Ahmed Ladan Mohammed, Eme Ekeng, Oluwatosin Wuraola Akande, Stephanie Ayres, et al.

    Objectives Nigeria reported an upsurge in cholera cases in October 2020, which then transitioned into a large, disseminated epidemic for most of 2021. This study aimed to describe the epidemiology, diagnostic performance of rapid diagnostic test (RDT) kits and the factors associated with mortality during the epidemic. Design A retrospective analysis of national surveillance data. Setting 33 of 37 states (including the Federal Capital Territory) in Nigeria. Participants Persons who met cholera case definition (a person of any age with acute watery diarrhoea, with or without vomiting) between October 2020 and October 2021 within the Nigeria Centre for Disease Control surveillance data. Outcome measures Attack rate (AR; per 100 000 persons), case fatality rate (CFR; %) and accuracy of RDT performance compared with culture using area under the receiver operating characteristic curve (AUROC). Additionally, individual factors associated with cholera deaths and hospitalisation were presented as adjusted OR with 95% CIs. Results Overall, 93 598 cholera cases and 3298 deaths (CFR: 3.5%) were reported across 33 of 37 states in Nigeria within the study period. The proportions of cholera cases were higher in men aged 5–14 years and women aged 25–44 years. The overall AR was 46.5 per 100 000 persons. The North-West region recorded the highest AR with 102 per 100 000. Older age, male gender, residency in the North-Central region and severe dehydration significantly increased the odds of cholera deaths. The cholera RDT had excellent diagnostic accuracy (AUROC=0.91; 95% CI 0.87 to 0.96). Conclusions Cholera remains a serious public health threat in Nigeria with a high mortality rate. Thus, we recommend making RDT kits more widely accessible for improved surveillance and prompt case management across the country.


  • Open Access

    Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey

    by Rosemary A. Audu, Kristen A. Stafford, Laura Steinhardt, Zaidat A. Musa, Nnaemeka Iriemenam, Elsie Ilori, Natalia Blanco, Andrew Mitchell, Yohhei Hamada, Mirna Moloney, et al.

    The observed epidemiology of SARS-CoV-2 in sub-Saharan Africa has varied greatly from that in Europe and the United States, with much lower reported incidence. Population-based studies are needed to estimate true cumulative incidence of SARS-CoV-2 to inform public health interventions. This study estimated SARS-CoV-2 seroprevalence in four selected states in Nigeria in October 2020. We implemented a two-stage cluster sample household survey in four Nigerian states (Enugu, Gombe, Lagos, and Nasarawa) to estimate age-stratified prevalence of SARS-CoV-2 antibodies. All individuals in sampled households were eligible for interview, blood draw, and nasal/oropharyngeal swab collection. We additionally tested participants for current/recent malaria infection. Seroprevalence estimates were calculated accounting for the complex survey design. Across all four states, 10,629 (96·5%) of 11,015 interviewed individuals provided blood samples. The seroprevalence of SARS-CoV-2 antibodies was 25·2% (95% CI 21·8–28·6) in Enugu State, 9·3% (95% CI 7·0–11·5) in Gombe State, 23·3% (95% CI 20·5–26·4) in Lagos State, and 18·0% (95% CI 14·4–21·6) in Nasarawa State. Prevalence of current/recent malaria infection ranged from 2·8% in Lagos to 45·8% in Gombe and was not significantly related to SARS-CoV-2 seroprevalence. The prevalence of active SARS-CoV-2 infection in the four states during the survey period was 0·2% (95% CI 0·1–0·4). Approximately eight months after the first reported COVID-19 case in Nigeria, seroprevalence indicated infection levels 194 times higher than the 24,198 officially reported COVID-19 cases across the four states; however, most of the population remained susceptible to COVID-19 in October 2020.


  • Open Access

    COVID-19 mortality rate and its associated factors during the first and second waves in Nigeria

    by Kelly Elimian, Anwar Musah, Carina King, Ehimario Igumbor, Puja Myles, Olaolu Aderinola, Cyril Erameh, William Nwanchukwu, Oluwatosin Akande, Ndembi Nicaise, et al.

    COVID-19 mortality rate has not been formally assessed in Nigeria. Thus, we aimed to address this gap and identify associated mortality risk factors during the first and second waves in Nigeria. This was a retrospective analysis of national surveillance data from all 37 States in Nigeria between February 27, 2020, and April 3, 2021. The outcome variable was mortality amongst persons who tested positive for SARS-CoV-2 by Reverse-Transcriptase Polymerase Chain Reaction. Incidence rates of COVID-19 mortality was calculated by dividing the number of deaths by total person-time (in days) contributed by the entire study population and presented per 100,000 person-days with 95% Confidence Intervals (95% CI). Adjusted negative binomial regression was used to identify factors associated with COVID-19 mortality. Findings are presented as adjusted Incidence Rate Ratios (aIRR) with 95% CI. The first wave included 65,790 COVID-19 patients, of whom 994 (1∙51%) died; the second wave included 91,089 patients, of whom 513 (0∙56%) died. The incidence rate of COVID-19 mortality was higher in the first wave [54∙25 (95% CI: 50∙98–57∙73)] than in the second wave [19∙19 (17∙60–20∙93)]. Factors independently associated with increased risk of COVID-19 mortality in both waves were: age ≥45 years, male gender [first wave aIRR 1∙65 (1∙35–2∙02) and second wave 1∙52 (1∙11–2∙06)], being symptomatic [aIRR 3∙17 (2∙59–3∙89) and 3∙04 (2∙20–4∙21)], and being hospitalised [aIRR 4∙19 (3∙26–5∙39) and 7∙84 (4∙90–12∙54)]. Relative to South-West, residency in the South-South and North-West was associated with an increased risk of COVID-19 mortality in both waves. In conclusion, the rate of COVID-19 mortality in Nigeria was higher in the first wave than in the second wave, suggesting an improvement in public health response and clinical care in the second wave. However, this needs to be interpreted with caution given the inherent limitations of the country’s surveillance system during the study.


  • Open Access

    Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria

    by Nnaemeka C. Iriemenam, Fehintola A. Ige, Stacie M. Greby, Augustine Mpamugo, Ado G. Abubakar, Ayuba B. Dawurung, Mudiaga K. Esiekpe, Andrew N. Thomas, Mary U. Okoli, Samuel S. Awala, et al.

    Objective: There is a need for reliable serological assays to determine accurate estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Most single target antigen assays have shown some limitations in Africa. To assess the performance of a multi-antigen assay, we evaluated a commercially available SARS-CoV-2 Multi-Antigen IgG assay for human coronavirus disease 2019 (COVID-19) in Nigeria. Methods: Validation of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was carried out using well-characterized SARS-CoV-2 reverse transcription polymerase chain reactive positive (97) and pre-COVID-19 pandemic (86) plasma panels. Cross-reactivity was assessed using pre-COVID-19 pandemic plasma specimens (213) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Results: The overall sensitivity of the xMAP SARS-CoV-2 Multi-Antigen IgG assay was 75.3% [95% CI: 65.8%– 82.8%] and specificity was 99.0% [95% CI: 96.8%– 99.7%]. The sensitivity estimate increased to 83.3% [95% CI: 70.4%– 91.3%] for specimens >14 days post-confirmation of diagnosis. However, using the NAIIS pre-pandemic specimens, the false positivity rate was 1.4% (3/213). Conclusions: Our results showed overall lower sensitivity and a comparable specificity with the manufacturer’s validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.